論文・技術情報追加のお知らせ

1. Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.

CDK4/6阻害剤は神経・精神の有害事象を早期に引き起こす可能性あり

対象DB：FAERS

2. Combined nephrotoxicity of polymyxins and vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system.

バンコマイシンとポリミキシンBの併用は腎毒性を悪化させ、コリスチンとの併用は改善

対象DB：FAERS

3. Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database.

ソルリアンフェトールの副作用をFAERSで分析し、新たな副作用16件を確認

対象DB：FAERS

4. Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors.

免疫チェックポイント阻害剤による免疫性血小板減少症が確認。特にPD-1阻害剤が多い

対象DB：FAERS

5. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database.

ウパダシチニブの副作用を分析。男性は筋骨格系や皮膚障害、女性は感染症が多い

対象DB：FAERS

6. Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone.

フィネレノンの副作用を分析。腎機能低下や高カリウム血症が多く報告

対象DB：FAERS

7. Drug-associated congenital anomalies of the external ear identified in the United States food and drug administration adverse event reporting system database.

外耳の先天異常と薬剤の関連を調査。バルプロ酸が最も多く関与

対象DB：FAERS

8. Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database.

ルフィナミドの副作用を評価。新たな有害事象が確認された

対象DB：FAERS

9. Analysis of the Incidence and Factors Influencing Medication Administration Errors Among Nurses: A Retrospective Study.

看護師の薬剤投与ミスの要因を調査。年齢や環境が影響

対象DB：FAERS

10. Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System.

レズリズマブの副作用分析を実施。新たな副作用が確認された

対象DB：FAERS

11. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).

FLT3阻害剤の副作用シグナルをFAERSで分析

対象DB：FAERS

12. Mining and evaluation of adverse event signals for capmatinib based on the FAERS database.

カプマチニブの新たな副作用をFAERSで特定

対象DB：FAERS

13. Development and validation of a clinical prediction model for osteonecrosis of the jaw in patients receiving zoledronic acid using FAERS and canadian databases.

ゾレドロン酸治療の顎骨壊死予測モデルを開発・検証

対象DB：CVAR,FAERS

14. Regional diversity in drug-induced lung diseases among the USA, European Union, and Japan.

日本、EU、米国で薬剤性肺疾患の発生率に地域差が確認された

対象DB：FAERS

15. A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system.

リスペリドンは高プロラクチン血症リスクが最大で、女性や中年層に多い

対象DB：FAERS

16. Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database.

抗ヘルペスウイルス薬の副作用に違いがあり、ガンシクロビルは血液毒性が高い

対象DB：FAERS

17. Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.

ルマテペロンの副作用は、女性や双極性障害II型でリスクが高い

対象DB：FAERS

18. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.

CDK4/6阻害剤に新たな副作用シグナルが確認され、注意が必要

対象DB：FAERS

19. Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.

リメゲパンの副作用には新たな症状があり、さらなる研究が必要

対象DB：FAERS

20. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).

エスリカルバゼピンは皮膚障害のリスクを伴う

対象DB：FAERS

21. Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy.

MS治療薬がてんかん発症を抑制する可能性

対象DB：FAERS

22. Adverse Event Profile of First-line Drugs for Treating Patent Ductus Arteriosus in Neonates: A Disproportionality Analysis Study of USFDA Adverse Event Reporting System.

アセトアミノフェンはPDA治療で安全性が高い可能性

対象DB：FAERS

23. Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases.

免疫チェックポイント阻害剤に関連するGI有害事象を分析

対象DB：EudraVigilance

24. Clinical characteristics and outcomes of preterm versus term uterine rupture: a nationwide observational study.

子宮破裂は、妊娠週数で異なる合併症を伴う

対象DB：DPC

25. Outcomes of low-dose trimethoprim-sulfamethoxazole treatment in patients with non-HIV pneumocystis pneumonia: A nationwide Japanese retrospective cohort study.

非HIV患者のPCPに低用量TMP-SMXが有効である可能性

対象DB：DPC

26. Pollen as a mediator between environmental greenness during pregnancy and infancy periods and childhood persistent asthma: A nationwide retrospective birth cohort study in Japan.

都市部で緑地と小児喘息の関連が確認された

対象DB：JMDC

27. Current situation and trends of radiation therapy in Japan based on the National Database Open Data.

日本の放射線治療の現状と地域差を可視化

対象DB：NDB

28. Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan.

リポ蛋白(a)と動脈硬化性心疾患の関連を日本で調査

対象DB：MDV

29. Risk of Venous Thromboembolism in Statin Users Compared to Fibrate Users in the United Kingdom Clinical Practice Research Datalink (UK CPRD) GOLD.

スタチンは静脈血栓塞栓症リスクを低減する可能性あり

対象DB：CPRD

30. Referral to pulmonary rehabilitation and palliative care services in people with idiopathic pulmonary fibrosis in England, 2010-2019.

IPF患者のPR・PC紹介率が低く、地域差も確認

対象DB：CPRD

31. Recording of Alcohol Use Disorder in Electronic Health Records: Developing a Recommended Codelist for Research.

英国EHRでAUDコードリストを開発し、研究向けに分類

対象DB：CPRD

32. The Prevalent New-User Design to Study Drug-Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia.

併用薬のDDI影響を調査し、有効性を確認

対象DB：CPRD

33. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.

LIFE-CVD2は、地域別に心血管疾患リスクを予測し予防策を支援するモデル

対象DB：CPRD